BioWorld

Jan. 24, 2005

View Archived Issues

Amylin Publicly Raises $176M To Fund Symlin, Exenatide Plans

Read More

Mutations In Mitochondrion Affect Prostate Cancer Risk

Read More

Schering-Plough Plans Buyout Of Platform Firm NeoGenesis

Read More

Chelsea Joins With Ivory Capital, Goes Public Via Reverse Merger

Read More

ViaCell Prices At Low End, But Gets $52.5M In 2005's First IPO

Read More

Other News To Note

Read More

Ambit Hits A Triple, Signs BMS, GSK, Pfizer To Deals

Ambit Biosciences Inc.'s super-multi-tasking approach to kinase screening bagged the company deals with three of pharma's top players - Bristol-Myers Squibb Co., GlaxoSmithKline plc and Pfizer Inc. (BioWorld Today) Read More